Gardasil™: Anti-papilloma virus vaccine

Drugs of the Future

Volumn 31, Issue 2, 2006, Pages 97-100

  McIntyre, J A ^a   Leeson, P A ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXYPHOSPHATE SULFATE; CAPSID PROTEIN; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CLINICAL TRIAL; DRUG FORMULATION; DRUG TOLERABILITY; GYNECOLOGIC DISEASE; HEADACHE; HUMAN; IMMUNIZATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; PAPILLOMA VIRUS; REVIEW; SEROCONVERSION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS PARTICLE;

EID: 33646248293     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.02.967420     Document Type: Review

References (27)

1. Trottier, H., Franco, E.L. The epidemiology of genital human papillomavirus infection. Vaccine 2006, Advance publication.
2. Kahn, J.A. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health 2005, 37(6, Suppl.): S10-6.
3. Bosch, F.X., de Sanjose, S. Chapter 1: Human papillomavirus and cervical cancer - Burden and assessment of causality. J Natl Cancer Inst Monogr 2003, (31): 3-13.
4. Bosch, F.X., Lorincz, A., Muñoz, N., Meijer, C.J.L.M., Shah, K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55: 244-65.
5. Bosch, F.X., de Sanjose, S. Human papillomavirus in cervical cancer. Curr Oncol Rep 2002, 4:175-83.
6. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P. Global cancer statistics, 2002. CA - Cancer J Clin 2005, 55: 74-108.
7. Koutsky, L. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102: 3-8.
8. O'Mahony, C. Genital warts: Current and future management options. Am J Clin Dermatol 2005, 6: 239-43.
9. Brinkman, J.A., Caffrey, A.S., Muderspach, L.I., Roman, L.D., Kast, W.M. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: Consequences for clinical management. Eur J Gynaecol Oncol 2005, 26: 129-42.
10. Gardasil BLA granted priority review. DailyDrugNews.com (Daily Essentials) February 8, 2006.
11. Palker, T.J., Monteiro, J.M., Martin, M.M., Kakareka, C., Smith, J.F., Cook, J.C., Joyce, J.G., Jansen, K.U. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 2001, 19: 3733-43.
12. Ruiz, W., McClements, W.L., Jansen, K.U., Esser, M.T. Kinetics and isotype profile of antibody response in rhesus macaques induced following vaccination with HPV 6. 11. 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 2005, 3(1): 2.
13. Ault, K.A., Giuliano, A.R., Edwards, R.P. et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004, 22: 3004-7.
14. Koutsky, L.A., Ault, K.A., Wheeler, C.M. et al. A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Med 2002, 347: 1645-51.
15. Poland, G.A., Jacobson, R.M., Koutsky, L.A., Tamms, G.M., Railkar, R., Smith, J.F., Bryan, J.T., Cavanaugh, P.F. Jr., Jansen. K.U., Barr, E. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2-year randomized controlled clinical trial. Mayo Clin Proc 2005, 80: 601-10.
16. Villa, L.L., Costa, R.L., Petta, C.A. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6: 271-8.
17. Nolan, T., Block, S.L., Reisinger, K.S., Marchant, C.D., Rusche, S.A., Lledo, L.R., Sattler, C., Li, H., Cavanaugh, P.F. Jr., Barr, E. Comparison of the immunogenicity and tolerability of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 17, 18) L1 virus-like particle (VLP) vaccine in male and female adolescents and young adult women. 23rd Annu Meet Eur Soc Paediatr Infect Dis (May 18-20, Valencia) 2005, Abst.
18. Sattler, C. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington DC) 2005, Abst LB2-25.
19. Skjeldestad, F.E. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. 43rd Annu Meet Infect Dis Soc Am (IDSA) (Oct 6-9, San Francisco) 2005, Abst LB-8a.
20. Merck's investigational vaccine Gardasil™ prevented 100 percent of cervical pre-cancers and non-invasive cervical cancers associated with HPV types 16 and 18 in new clinical study. Merck & Co., Inc. Press Release 2005, October 6.
21. Cervical intraepithelial neoplasm (CIN) in women (NCT00092534). ClinicalTrials.gov Web Site 2006, February 3.
22. Immunogenicity bridge between an investigational monovalent vaccine and the equivalent component of an investigational quadrivalent vaccine (NCT00092482). ClinicalTrials.gov Web Site 2006, February 3.
23. An investigational vaccine in reducing the incidence of anogenital warts in young men (NCT00090285). ClinicalTrials.gov Web Site 2006, February 17.
24. A study to evaluate the safety, immune response, and efficacy of an investigational vaccine in women (NCT00090220). ClinicalTrials.gov Web Site 2006, February 17.
25. Cervical intraepithelial neoplasm (CIN)-warts efficacy trial in women (NCT00092521). ClinicalTrials.gov Web Site 2006. February 17.
26. HPV registration study (NCT00157950). ClinicalTnals.gov Web Site 2006, February 17.
27. Study of an investigational vaccine in pre-adolescents and adolescents (NCT00092495). ClinicalTrials.gov Web Site 2006, February 17.